At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 77 enrolled
Drug / intervention
TAK-063 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Subjects With Stable Schizophrenia and Healthy Japanese Subjects
In Brief
A Phase 1 clinical trial evaluating TAK-063 and TAK-063 Placebo for Schizophrenia. Completed, enrolled 77 participants across 1 site.
Detailed Summary
The purpose of this study is to characterize the safety and tolerability of TAK-063 when administered as multiple oral doses at escalating dose levels in participants with stable schizophrenia and in healthy Japanese participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJun 2013
First PostedJun 2013
Primary CompletionJun 2014
TodayJul 2026
First PostedJun 18, 2013
Enrollment StartJun 1, 2013
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 13.0 years ago
Interventions
TAK-063drug
TAK-063 tablets
TAK-063 Placebodrug
TAK-063 placebo-matching tablets